Research and Markets has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2016" drug pipelines to their offering.
Viral Conjunctivitis Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.
Viral Conjunctivitis pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II and Preclinical stages are 2 and 4 respectively.
Viral Conjunctivitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jh7kpf/viral
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006218/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.